Group 1 - The article emphasizes that the Securities Times is a key platform for authoritative information disclosure in the Chinese capital market [1] - It provides comprehensive financial and securities information 24/7, including market news, financial updates, fund values, bonds, futures, and company announcements [1] - The platform has developed the "Information Disclosure 168" service area and the "Spark Plan" for investor education, reinforcing its role as a comprehensive service platform for the capital market [1]

东阿阿胶声明：阿胶浆药品追溯码重复 初步调查非我公司原因 财联社11月2日电，东阿阿胶发布声明 称，近期，我公司关注到部分复方阿胶浆追溯码有重复现象后，第一时间对接国家医保局，并在其专业 指导下开展调查工作。 东阿阿胶生产的所有复方阿胶浆产品，均按照国家有关法律法规执行，严格执行一药一码。 国家医保局《关于对复方阿胶浆药品追溯码重复情况开展核查的公告》中所提及的追溯码重复现象非我 公司原因。 目前，我公司正在积极协助有关部门开展工作，同时欢迎社会各界朋友提供线索和帮助。 ...

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 70.4 CNY, compared to the current price of 58.86 CNY [1]. Core Insights - The company reported a revenue of 4.33 billion CNY for the first three quarters of 2024, representing a 26% year-over-year increase, and a net profit of 1.15 billion CNY, up 47% year-over-year [1]. - The core products, including Ejiao blocks, paste, and cakes, are expected to show stable growth, with significant increases in sales driven by marketing efforts and policy changes [1]. - The management team has undergone changes, with a focus on enhancing shareholder returns, including a substantial cash dividend of 7.37 billion CNY, which accounts for 99.77% of the net profit for the first half of 2024 [1]. Financial Performance Summary - For 2024, the company is projected to achieve total revenue of 5.91 billion CNY, a 25.4% increase from 2023, and a net profit of 1.49 billion CNY, reflecting a 29.6% growth [2]. - The gross margin for Q3 2024 improved by 3.2 percentage points to 75.1%, while the net margin increased by 6.1 percentage points to 26.1% [1]. - The company’s operating cash flow for the first three quarters of 2024 was 1.44 billion CNY, indicating healthy cash flow management [1]. Product Performance - Ejiao blocks are expected to see double-digit growth in revenue for the first three quarters of 2024, supported by ongoing brand enhancement initiatives [1]. - Ejiao paste is projected to grow by 40-50% in revenue due to favorable policy changes and marketing strategies [1]. - Ejiao cakes are anticipated to grow by 15-20% in the same period, with online channels contributing to the revenue growth of Ejiao powder, which is expected to exceed 100 million CNY [1].

股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 编号：2024-06 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 √业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 | 中信建投、中泰证券等券商分析师及广大投资者朋友 | | 及人员姓名 | | | 时间 | 2024 年 10 月 31 日 | | 地点 | 公司会议室 | | 上市公司 | 董事、董事会秘书、副总裁、财务总监 丁红岩 | | 接待人员姓名 | 证券事务代表、董事会办公室总经理 付延 | | | 一、公司总体情况介绍 2024 年，东阿阿胶围绕"增长·质量"关键主题，以汇聚新质生 | | | 产力为着力点，深度践行"四个重塑"。以品牌唤醒强化"滋补国宝 东 | | | 阿阿胶"顶流品牌地位，通过品牌焕新打造国潮特色新品牌，持续构建 | | | 药品+健康消费品"双轮驱动"业务增长模式，依托"一中心 三高地" | | 投资者关系活动 | 的研发布局，拓展新品类、推出新产品、开发新功效、吸 ...

◼ 风险提示：原料价格上涨、终端销售不及预期、高端消费疲软 2024 年 10 月 31 日 王睿哲 C0062@capital.com.tw 目标价(元) 71 | --- | --- | --- | --- | |-----------------------|-----------------|----------------|-------------------------| | 公司基本信息 | | | | | 产业别 | | | 医药生物 | | A 股价 (2024/10/30) | | | 59.23 | | 深证成指 (2024/10/30) | | | 10530.85 | | 股价 12 个月高/低 | | | 69.46/42.59 | | 总发行股数 (百万) | | | 643.98 | | A 股数(百万 ) | | | 643.98 | | A 市值(亿元) | | | 381.43 | | 主要股东 | | | 华润东阿阿胶 | | 每股净值(元 ) | | | 有限公司 (23.50%) 15.39 | | 股价/账面净值 | | | 3.85 | | | 一个月 | 三 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2024-59 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届监事会第三次会 议，于 2024 年 10 月 26 日以邮件方式发出会议通知。 2．本次监事会会议，于 2024 年 10 月 29 日以通讯表决方式召开。 3．会议应出席会议监事 5 人，实际出席会议监事 5 人。 4．本次监事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、监事会会议审议情况 本次会议审议并通过了以下议案： 东阿阿胶股份有限公司 第十一届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 经审议，监事会认为公司《2024 年第三季度报告》的编制，符合法律、法规、 中国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整地反映了 公司实际经营情况，不存在任何虚假记载、误导性陈述或重大遗漏。 公司《2024 年第三季度报告》是按照中国证监会和深圳证券交易所颁发的 信息披露内容与格式准则等有关要求编制的，所包含内容真实反映了公司财务状 况 ...

Financial Performance - The company's revenue for Q3 2024 reached ¥1,581,271,320.36, representing a 25.38% increase year-over-year[6] - Net profit attributable to shareholders was ¥413,567,484.71, a significant increase of 63.75% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥367,356,380.51, up 74.53% year-over-year[6] - Basic earnings per share for the quarter were ¥0.6437, reflecting a 64.13% increase from the previous year[6] - Operating profit increased by 39.84% to ¥1,342,559,579.23 compared to the previous period, driven by sales revenue growth and improved gross margin[10] - Net profit rose by 46.74% to ¥1,152,145,315.53, attributed to increased sales revenue and enhanced gross margin[10] - Total profit increased by 41.20% to ¥1,348,692,004.91, influenced by sales revenue growth and improved gross margin[10] - Total operating revenue for the third quarter reached ¥4,329,229,198.62, an increase of 26.3% compared to ¥3,428,282,500.66 in the same period last year[18] - Net profit attributable to shareholders of the parent company was ¥1,151,986,622.87, up 47.0% from ¥783,673,380.90 in the previous year[19] - Operating profit for the period was ¥1,342,559,579.23, representing a 39.9% increase from ¥960,039,278.58 in the prior year[18] - The company reported a total profit of ¥1,348,692,004.91, an increase of 41.2% from ¥955,142,627.93 in the previous year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,715,273,642.98, a decrease of 4.44% from the end of the previous year[6] - The company's equity attributable to shareholders decreased by 7.53% to ¥9,911,873,728.09 compared to the previous year[6] - Total assets decreased from CNY 13,306,306,533.41 at the beginning of the period to CNY 12,715,273,642.98 at the end of the period, representing a decline of approximately 4.44%[15] - Current assets decreased from CNY 10,536,889,490.97 to CNY 9,912,427,903.38, a reduction of about 5.91%[15] - Total liabilities increased from CNY 2,565,744,617.42 to CNY 2,781,693,939.85, an increase of approximately 8.43%[16] - Current liabilities increased from CNY 2,406,763,444.39 to CNY 2,635,564,233.00, an increase of about 9.52%[16] - The company's equity decreased from CNY 9,208,565,999.56 to CNY 8,477,565,068.86, a decline of approximately 7.95%[16] Cash Flow - Cash inflow from investment activities totaled ¥5,274,336,106.81, a 58.17% increase year-on-year, primarily due to the recovery of funds from financial products[10] - Cash outflow for investment activities reached ¥6,266,979,059.74, a 99.18% increase compared to the previous period, mainly due to increased financial product purchases[10] - Cash flow from operating activities was ¥4,130,691,699.34, compared to ¥3,564,807,491.53 in the same period last year, indicating a growth of 15.8%[20] - Operating cash inflow totaled CNY 4,247,132,197.06, an increase of 15.2% compared to CNY 3,687,681,692.33 in the previous year[21] - Net cash outflow from investment activities was CNY -992,642,952.93, a decrease from CNY 188,077,996.21 in the same period last year[21] - Cash received from investment activities was CNY 5,274,336,106.81, up from CNY 3,334,503,474.51 in the previous year[21] - Cash paid for investment activities was CNY 6,266,979,059.74, compared to CNY 3,146,425,478.30 in the same period last year[21] - Total cash outflow from financing activities reached CNY 1,967,729,659.15, compared to CNY 761,964,461.19 in the previous year[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,998, with the largest shareholder holding 23.50% of the shares[11] - The top ten shareholders collectively held 32.50% of the company's total share capital[12] Research and Development - Research and development expenses increased to ¥89,467,158.11, slightly up from ¥85,626,885.58 in the previous year[18] Product Development and Market Strategy - The company is expanding its product line with new offerings such as the "Peach Blossom Princess Ejiao Cake" and "Ejiao Instant Powder" targeting health-conscious consumers[4] - The company plans to enhance its market presence by focusing on male health supplements and leveraging proprietary technology for product development[4] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Expenses and Impairments - Management expenses rose by 31.45% to ¥275,885,485.14, mainly due to personnel growth and adjustments in social security and compensation[10] - Asset impairment losses increased by 226.88% to ¥33,159,225.80, influenced by the reversal of some asset impairment losses from inventory disposal[10] - The company reported a significant increase in cash paid to employees, totaling CNY 564,826,412.71, compared to CNY 472,591,156.35 in the previous year[21]

一、董事会会议召开情况 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第三次会 议，于 2024 年 10 月 26 日以邮件方式发出会议通知。 2．本次董事会会议，于 2024 年 10 月 29 日以通讯表决方式召开。 3．会议应出席会议董事 7 人，实际出席会议董事 7 人。 4．本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 证券代码：000423 证券简称：东阿阿胶 公告编号：2024-58 东阿阿胶股份有限公司 第十一届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 表决结果：7 票同意，0 票反对，0 票弃权。 3．《关于制定<规章制度管理规定>的议案》 二、董事会会议审议情况 本次会议审议并通过了以下议案： 1．《关于 2024 年第三季度报告的议案》 本议案提交董事会前，已经公司第十一届董事会审计委员会审议通过。 经审议，董事会认为公司《2024 年第三季度报告》的编制，符合法律、法规、 中国证监会和深圳证券交易所的相关规定。报告内容真实、准确、完整地反映了 公司实 ...

东阿阿胶股份有限公司 投资者关系管理制度 （2024 年 10 月 29 日 经公司第十一届董事会第三次会议审议通过） 第一章 总则 第一条 为加强东阿阿胶股份有限公司（以下简称"公司"）与 投资者及潜在投资者（以下统称为"投资者"）的信息沟通，加深投 资者对公司的了解和认同，形成公司与投资者之间长期、稳定的良性 互动关系，最终实现公司价值和股东利益最大化，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司投资者关系管理工 作指引》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》《东阿阿胶股份有 限公司章程》（以下简称"《公司章程》"）及相关法律法规等规定，结 合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息 | --- | |--------------------------------------------------------------| | | | | | 披露、互动交流和诉求处理等工作，加强与投资者之间的沟通，增进 | | 投资者对公司的了解和认同，以提升公司治理水平和企业整体价值， ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2024-61 东阿阿胶股份有限公司 关于对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 东阿阿胶股份有限公司（以下简称"东阿阿胶"或"公司"）于 2024 年 10 月 29 日召开第十一届董事会第三次会议，审议通过了《关于对外捐赠的议案》。 现将有关情况公告如下： 一、对外捐赠事项概述 为积极响应关于健康中国建设以及乡村振兴战略号召，支持华润健康乡村公 益项目，助力国家现代医学教育体系建设，公司拟向中国妇女发展基金会和中国 医学科学院捐赠人民币 530 万元。其中，向中国妇女发展基金会捐赠人民币 430 万元，包括现金捐赠 350 万元人民币和实物捐赠价值 80 万元人民币，用于助力 华润健康乡村公益项目；向中国医学科学院捐赠人民币 100 万元，用于支持中国 医学科学院学术咨询委员会相关活动以及国家现代医学教育体系建设等工作。 二、对公司的影响 本次对外捐赠旨在进一步改善基层百姓就医环境，为乡村振兴及国家现代医 学教育体系建设贡献力量，是公司积极履行社会责任及回馈社会的具体实践。 本次 ...